Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
Is There Room for Latecomers to the COVID-19 Party?
07:28am, Saturday, 21'st Nov 2020
Despite multiple treatments, vaccines, and tests for COVID-19 developed by leading competitors, Sorrento's CEO Henry Ji thinks the company still has an opportunity to thrive.
Exclusive: EU could pay over $10 billion for Pfizer and CureVac vaccines - source
01:04am, Friday, 20'th Nov 2020
The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talk
Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO
10:48am, Wednesday, 18'th Nov 2020
Nov.18 -- CureVac Chief Executive Officer Franz-Werner Haas discusses the progress on the biopharmaceutical company's Covid-19 vaccine and scale-up for its production on “Bloomberg Surveillance.”
German vaccine maker CureVac ramps up capacity to 300 million COVID-19 doses in 2021
10:54am, Tuesday, 17'th Nov 2020
CureVac expects to announce partnerships with vaccine developers and manufacturers in coming weeks to ramp up capacity of its potential vaccine candidate.
3 mRNA Coronavirus Vaccine Stocks to Check Out That Aren't Pfizer, BioNTech, or Moderna
06:04am, Tuesday, 17'th Nov 2020
Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.
3 Best Biotech Stocks to Buy Right Now
05:24am, Saturday, 14'th Nov 2020
Biotech is on every investor's mind as we move closer and closer to a successful vaccine for the coronavirus. Here are three contenders for your portfolio.
CureVac Rallies On Interim Phase 1 Data For COVID-19 Vaccine Candidate: What You Need To Know
11:34am, Tuesday, 10'th Nov 2020
German biopharma CureVac BV (NASDAQ: CVAC) — which is developing an mRNA vaccine against the novel coronavirus — was rallying Tuesday following the release of detailed interim Phase 1 data for
CureVac's stock is up 8% as it shares additional Phase 1 data about its COVID-19 vaccine candidate
08:04am, Tuesday, 10'th Nov 2020
Shares of CureVac gained 8.0% in premarket trading on Tuesday after the company disclosed additional clinical data about how its COVID-19 vaccine candidate is performing in a Phase 1 clinical trial. I
CureVac Reports Early-Stage Data for Its Coronavirus Vaccine Candidate
02:41pm, Monday, 02'nd Nov 2020
Participants in the phase 1 clinical trial mounted an immune response after being inoculated with CVnCoV.
CureVac Posts Positive Early Data For Its Covid-19 Vaccine Candidate
11:33am, Monday, 02'nd Nov 2020
Recent hot IPO CureVac reported positive Phase 1 clinical trials data for its Covid-19 vaccine candidate, which is among a number based on mRNA technology. CVAC stock rose on the news.
CureVac's COVID-19 vaccine shows immune response in Phase 1 trial
10:54am, Monday, 02'nd Nov 2020
German biotech CureVac said advanced clinical trials are on track to launch by the end of 2020.
Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global Pact
07:07am, Tuesday, 27'th Oct 2020
The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.
U.S. IPO Week Ahead: No IPOs, But Plenty Of Potential Launches In The Short Holiday Week
01:14pm, Sunday, 06'th Sep 2020
Just one SPAC is scheduled for the week ahead. More SPACs may join the IPO calendar, and another wave of new filings will likely hit after Labor Day as well.
Wall Street Breakfast: The Week Ahead
04:42am, Sunday, 06'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
08:21am, Saturday, 05'th Sep 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
